Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Gartrell

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Cancer Discovery|May 3, 2020
Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital SystemVikas Mehta, Sanjay Goel, Rafi Kabarriti, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 14, 2019
Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 casesLiwei Jia, Maria I Carlo, Hina Khan, et al.
The Journal of Clinical Investigation|April 23, 2024
Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profilesPedro Barata, Shuchi Gulati, Andrew Elliott, et al.
British Journal of Cancer|November 11, 2023
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTANJohn Shen, Simon Chowdhury, Neeraj Agarwal, et al.
JNCI Cancer Spectrum|June 3, 2022
The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate CancerNeil J Shah, Vaibhav G Patel, Xiaobo Zhong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2022
Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA TrialChung-Han Lee, Robert Motzer, Hamid Emamekhoo, et al.
Hypertension (Dallas, Tex. : 1979)|May 20, 2026
Cluster Randomized Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191Bonnie Ky, Tao Liu, Kenneth B Margulies, et al.
Clinical Genitourinary Cancer|August 8, 2021
A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry ExperienceBrian A Costello, Nrupen A Bhavsar, Yousef Zakharia, et al.
Cancer|March 25, 2021
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)Michael R Harrison, Brian A Costello, Nrupen A Bhavsar, et al.
The Journal of Urology|January 24, 2020
Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective StudyNatalie J Miller, Ali Raza Khaki, Leonidas N Diamantopoulos, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Cancer Discovery|May 3, 2020
Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital SystemVikas Mehta, Sanjay Goel, Rafi Kabarriti, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 14, 2019
Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 casesLiwei Jia, Maria I Carlo, Hina Khan, et al.
The Journal of Clinical Investigation|April 23, 2024
Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profilesPedro Barata, Shuchi Gulati, Andrew Elliott, et al.
British Journal of Cancer|November 11, 2023
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTANJohn Shen, Simon Chowdhury, Neeraj Agarwal, et al.
JNCI Cancer Spectrum|June 3, 2022
The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate CancerNeil J Shah, Vaibhav G Patel, Xiaobo Zhong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2022
Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA TrialChung-Han Lee, Robert Motzer, Hamid Emamekhoo, et al.
Hypertension (Dallas, Tex. : 1979)|May 20, 2026
Cluster Randomized Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191Bonnie Ky, Tao Liu, Kenneth B Margulies, et al.
Clinical Genitourinary Cancer|August 8, 2021
A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry ExperienceBrian A Costello, Nrupen A Bhavsar, Yousef Zakharia, et al.
Cancer|March 25, 2021
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)Michael R Harrison, Brian A Costello, Nrupen A Bhavsar, et al.
The Journal of Urology|January 24, 2020
Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective StudyNatalie J Miller, Ali Raza Khaki, Leonidas N Diamantopoulos, et al.
Pageof 5